Sign in
GeneticsNature Communications
Peer-reviewed journal article

Evaluating transportability of in-vitro cellular models to in-vivo human phenotypes using gene perturbation data

Laurence J HoweiD, Yurii S. AulchenkoiD, George Davey SmithiD, Neil M DaviesiD, Jorge Esparza-Gordillo, Toby JohnsoniD, Jimmy Z. LiuiD, Tom G. RichardsoniD, Philippe Sanséau, Robert A. ScottiD, Daniel D. SeatoniD, Ashwini Kumar SharmaiD, Adrián CortésiD

Abstract

Gene perturbation screens (e.g. CRISPR-Cas9) assess the impact of gene disruption on in-vitro cellular phenotypes (e.g., proliferation, anti-viral response, transcriptomics). In-vitro experiments can be useful models for understanding the aetiology of in-vivo (organismal) phenotypes. For example, anti-viral response in immune cells and infectious disease outcomes. However, assessing whether an in-vitro cellular model is effectively capturing in-vivo biology is challenging. An in-vitro model is transportable to an in-vivo phenotype of interest if perturbations impacting the in-vitro phenotype also impact the in-vivo phenotype with mechanism-consistent directionality and effect sizes. We propose a framework; Gene Perturbation Analysis for Transportability (GPAT), to assess model transportability using gene perturbation effect estimates from perturbation screens (in-vitro cellular phenotypes) and loss-of-function burden tests (in-vivo phenotypes). Using UK Biobank whole-genome sequence data and data from published genome-wide CRISPR-Cas9 screens, we evaluated transportability of in-vitro cellular models to in-vivo human phenotypes. In hypothesis-driven analyses, we found evidence that higher lysosomal cholesterol accumulation in-vitro is a transportable model for lower LDL-cholesterol measured in human blood plasma (P = 0.0006), consistent with the known role of lysosomes in lipid biosynthesis. In contrast, we found limited evidence for other putative in-vitro models. In hypothesis-free analyses, we found strong evidence for transportability of proliferation in cancer cell lines for in-vivo human plasma cellular phenotypes. For example, higher proliferation in an erythroleukemia cell line and lower plasma lymphocyte percentage. GPAT enables systematic evaluation of the transportability of in-vitro cellular models to in-vivo phenotypes, informing assay prioritization and supporting novel hypothesis generation.

PDFDOI

02 /Specification & Classification

Click any tag to browse matching papers

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.